ArticleJournal of medical virology2025
Respiratory Syncytial Virus (RSV) in an Italian Pediatric Cohort: Genomic Analysis and Circulation Pattern in the Season 2022-2023.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genomic evolution and minority variant dynamics of RSV during the first season of nirsevimab implementation in Italy (2024-5).Virus evolution · 2026Article
- Prevalence and genetic diversity of respiratory syncytial viruses circulating in Bulgaria, 2023-2025.Frontiers in cellular and infection microbiology · 2026Article
- Respiratory Syncytial Virus (RSV) in an Italian Pediatric Cohort: Genomic Analysis and Circulation Pattern in the Season 2022-2023.Journal of medical virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There is growing interest in the molecular surveillance of the respiratory syncytial virus (RSV) and data concerning the virus molecular epidemiology in high-risk pediatric patients in Italy are still limited. A total of 127 RSV-positive swabs collected in 2022-2023 season were analyzed. Whole genomes were obtained by next-generation sequencing and used for phylogenetic and phylodynamic analyses. A large proportion of the subjects had required hospitalization (78%) and age of hospitalized subjects was significantly lower than that of nonhospitalized (69 vs. 129 days; p < 0.0001). Genomic analysis suggested a significant increase in nucleotide variability in recent samples compared to previous waves and especially in subtype A. Phylogenetic analysis identified 14 and 16 clades including Italian strains in RSV-A and B, respectively. Italian strains tended to group together forming monophyletic groups, 9 in RSV-A and 13 in RSV-B, probably representing local chains of transmission. A few of those pure Italian subclades began in 21-22 wave and persisted for more than 1 year. For both subtypes the skyline plot showed two peaks in transmissions, the first between 2017 and 2019, followed by a temporary reduction in 2021 coinciding with the widespread use of control measures against COVID-19 and the second at the beginning of 2023. Accordingly, the Re estimates showed fluctuating values. This study suggests that the large circulation of RSV following pandemic restrictions is partly due to the introduction of viral strains already circulating across Europe, and partly to strains that persist in our region from one season to the next.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.